Influence of the defective metabolism of sparteine on its pharmacokinetics
- PMID: 499319
- DOI: 10.1007/BF00562060
Influence of the defective metabolism of sparteine on its pharmacokinetics
Abstract
Sparteine is metabolized by N1-oxidation, which in some subjects is defective. The defect has a pronounced effect on the kinetics of the drug. In nonmetabolisers elimination of sparteine proceeds entirely via renal excretion by a capacity-limited process, 99,9% of the dose being excreted as unchanged drug. In metabolisers the drug is mainly eliminated by metabolic degradation. Pronounced differences in beta-phase half-life and total plasma clearance were observed between metabolisers (156 min; 535 ml . min-1) and nonmetabolisers (409 min; 180 ml . min-1).
Similar articles
-
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.Eur J Clin Pharmacol. 1979 Sep;16(3):183-7. doi: 10.1007/BF00562059. Eur J Clin Pharmacol. 1979. PMID: 499318
-
Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine.Eur J Clin Pharmacol. 1986;31(1):69-72. doi: 10.1007/BF00870989. Eur J Clin Pharmacol. 1986. PMID: 3780830
-
Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation.Klin Wochenschr. 1985 Nov 15;63(22):1180-6. doi: 10.1007/BF01740595. Klin Wochenschr. 1985. PMID: 4079282
-
The influence of enzyme induction on polymorphic sparteine oxidation.Br J Clin Pharmacol. 1986 Jul;22(1):49-53. doi: 10.1111/j.1365-2125.1986.tb02879.x. Br J Clin Pharmacol. 1986. PMID: 3741726 Free PMC article.
-
Clinical pharmacokinetics of encainide.Clin Pharmacokinet. 1988 Mar;14(3):141-7. doi: 10.2165/00003088-198814030-00002. Clin Pharmacokinet. 1988. PMID: 3131058 Review.
Cited by
-
Addressing phenoconversion: the Achilles' heel of personalized medicine.Br J Clin Pharmacol. 2015 Feb;79(2):222-40. doi: 10.1111/bcp.12441. Br J Clin Pharmacol. 2015. PMID: 24913012 Free PMC article. Review.
-
Sparteine oxidation polymorphism in Greenlanders living in Denmark.Br J Clin Pharmacol. 1986 Oct;22(4):415-9. doi: 10.1111/j.1365-2125.1986.tb02911.x. Br J Clin Pharmacol. 1986. PMID: 3768256 Free PMC article.
-
The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.Mol Diagn Ther. 2006;10(3):135-51. doi: 10.1007/BF03256453. Mol Diagn Ther. 2006. PMID: 16771600 Review.
-
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.Eur J Clin Pharmacol. 1979 Sep;16(3):183-7. doi: 10.1007/BF00562059. Eur J Clin Pharmacol. 1979. PMID: 499318
-
Ethnic differences in drug metabolism.Clin Pharmacokinet. 1982 Sep-Oct;7(5):373-400. doi: 10.2165/00003088-198207050-00001. Clin Pharmacokinet. 1982. PMID: 6754206 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous